Epidemiology of Shiga Toxin-Producing Escherichia Coli Infections in Connecticut by Phan, Quyen  Nha
University of Connecticut
OpenCommons@UConn
UCHC Graduate School Masters Theses 2003 -
2010
University of Connecticut Health Center Graduate
School
June 2001
Epidemiology of Shiga Toxin-Producing
Escherichia Coli Infections in Connecticut
Quyen Nha Phan
Follow this and additional works at: https://opencommons.uconn.edu/uchcgs_masters
Recommended Citation
Phan, Quyen Nha, "Epidemiology of Shiga Toxin-Producing Escherichia Coli Infections in Connecticut" (2001). UCHC Graduate
School Masters Theses 2003 - 2010. 93.
https://opencommons.uconn.edu/uchcgs_masters/93
EPIDEMIOLOGY OF SHIGA TOXIN-PRODUCING
ESCHERICHIA COLI INFECTIONS IN CONNECTICUT
Quyen Nha Phan
B.A., Tufts University, 1996
A Thesis
Submitted in Partial Fulfillmem of the
Requiremems for the Degree of
Master of Public Health
at the
University of Connecticut
2001
APPROVAL PAGE
Master of Public Health Thesis
EPIDEMIOLOGY OF SHIGA TOXIN-PRODUCING
ESCHECHIA COLI INFECTIONS IN CONNECTICUT
Presented by
Quyen Nha Phan, B.A.
Major Advisor
Associate Advisor
Associate Advisor
Associate Advisor
Holger HanseVI.D., Dr.PH., F.A.C.E
mes Hadler, M.D., M.P.H.
Cartter, ’M.D., M.P.H.
Stephen Wd, Ph.D.
ACKNOWLEDGEMENTS
The completion of this thesis could not have been accomplished without the
support and guidance of a many individuals. I am sincerely grateful to all those who
provided me with encouragement and counsel along the way.
First and foremost, I would like to thank my advisors for their advice and
direction throughout the completion of this thesis" Major Advisor, Dr. Holger Hansen;
Associate Advisor, Dr. James Hadler; Associate Advisor, Dr. Matthew Cartter; and
Associate Advisor, Dr. Stephen Walsh. Their comments and suggestions were
invaluable. I am also obliged to Ms. Joan Segal and Ms. Nita Thompson of the MPH
Program Office for their support and assistance throughout my years with the program.
I would like to thank my colleagues at the Connecticut Department of Public
Health, Epidemiology Program and FoodNet project, and Ms. Heather Linardos, with
Perinatal Infectious Diseases for their endless encouragement. I would like to
particularly thank Ms. Patricia Mshar for her advice throughout the study and Mr.
Robert Howard and Mr. Charles Welles for their invaluable work in the laboratory
component of this study. I am grateful and indebted to Dr. Tara McCarthy for her
vision, guidance, and enthusiasm for this important project.
Finally, I am grateful to my family. With their unconditional support, there are
no insurmountable obstacles.
iii
TABLE OF CONTENTS
Introduction
Background
Microbiology and Diagnosis
Pathogenesis
Clinical Manifestations
Prevalence
Transmission and Risk Factors 10
Methods 13
Laboratory Procedures 13
Ascertainment of Case-Patients and Control-Patients 14
Enrollment and Interview Procedures 14
Data Analysis 15
Results 17
Laboratory Surveillance 17
Crude Incidence, Projected Incidence and Seasonal Variation 18
Patient Characteristics 19
Spectrum of Illness 19
Exposures and Risk Factors 2O
Discussion 22
Tables 27
iv
Figures 33
References 35
Appendix 39
LIST OF TABLES
Table 1. Non-O157 STEC serotypes, Connecticut, February 1, 2000-
January 31,2001.
27
Table 2. Comparison of Case-Patients (non-O157) and Control Group 1 Patients
(all O157) by Demographic Factors, Connecticut, February 1, 2000-
January 31, 2001.
28
Table 3. Comparison of Case-Patients (non-O157) and Control Group 2 Patients
(STEC O157) by Demographic Factors, Connecticut, February 1, 2000-
January 31,2001.
29
Table 4. Comparison of Case-Patients (non-O157) and Control Group 1 Patients
(all O157) by Symptoms and Complications, Connecticut, February 1, 2000-
January 31,2001.
30
Table 5. Comparison of Case-Patients (non-O157) and Control Group 2 Patients
(STEC O157) by Symptoms and Complications, Connecticut, February 1, 2000
January 31,2001.
31
Table 6. Differences in Selected Exposures Between Case-Patients and Control-
Patients, Connecticut, February 1, 2000 January 31, 2001.
32
vi
LIST OF FIGURES
Figure 1. Monthly Distribution of STEC Infections, Connecticut,
February 1, 2000 January 31, 2001.
33
Figure 2. Season Distribution of STEC Infections, Connecticut,
February 1, 2000- January 31, 2001.
34
vii

INTRODUCTION
Infections with Shiga toxin-producing Escherichia coli (STEC) are an important
public health problem. E. coli O157:H7 is the most common STEC in the United
States and was first recognized as a human pathogen in 1982 during outbreaks of
hemorrhagic colitis associated with consumption of contaminated ground beef (1). It is
estimated that E. coli O157:H7 causes 73,000 infections each year in the US (2).
Hemolytic uremic syndrome (HUS), occurring mostly in young children, is a rare, but
potentially fatal complication of E. coli O157:H7 infection.
Although much has been learned about the clinical spectrum of disease, modes
of transmission and long-term sequelae of E. coli O157"H7, much less is known about
non-O157 STEC serotypes. Studies in other countries suggest that disease caused by
non-O157 STEC is as prevalent as O157-related disease. In the US, non-O157 STEC
has only come to attention when associated with HUS or outbreaks.
Historically, laboratory testing for E. coli O157 does not detect non-O157
STEC. Recently however, methods for the rapid detection of Shiga toxin in stool
specimens have become commercially available and are being used by an increasing
number of clinical laboratories. A recent survey of clinical laboratories in Connecticut
found that the number of laboratories using non-culture based methods for detecting
STEC increased from 4 laboratories in 1999 to 7 in 2000. Correspondingly, the
percentage of stool specimens tested for Shiga toxin increased from 3 % to 30% (3).
E. coli 0157 infections have been laboratory reportable in Connecticut since
1992. The number of cases reported in Connecticut ranged from 19 in 1992 to 94 in
1999. During 1999, the Connecticut Department of Public Health (DPH) first became
aware that several laboratories in the state were transitioning from culture-based
methods for E. coli O157 testing to testing for Shiga toxin. This was problematic since
Shiga toxin-positive results were not reportable and isolates could not be recovered for
further testing. The recovery of isolates is crucial because it allows for confirmation
and further testing to characterize the strain of E. coli O157. Characterization of the
infecting strain is a valuable tool in outbreak detection and investigation.
The shift to testing for Shiga toxin complicated the DPH’s investigations of
several clusters of E. coli O157 infections in the summer and fall of 1999. In
recognition of challenges posed by changes in laboratory E. coli testing practices, the
DPH added Shiga toxin-related disease to the list of "Laboratory Reportable Significant
Findings" in January 2000. Clinical laboratories are required to report and submit
Shiga toxin-positive broth cultures to the DPH State Laboratory for confirmation and
identification of the causative organism. Thus, changing laboratory practices provide a
unique opportunity to better define the public health importance of non-O157 STEC
infections Connecticut.
In addition to laboratory-based surveillance, an epidemiologic study was begun
in February 2000. The objectives of this study are to" 1) determine the incidence of
STEC infections in Connecticut, 2) determine the frequency of non-O157 STEC
compared to O157 STEC from a subset of Shiga toxin-positive specimens, 3) assess the
spectrum of clinical illness associated with non-O157 STEC and O157 STEC, 4) assess
the differences in risk factors for acquiring non-O157 STEC and O157 STEC, and 5)
assess the utility of surveillance for Shiga toxin-producing organisms as an alternative
or a complement to surveillance solely for E. coli 0157.
BACKGROUND
Microbiology and Diagnosis
Shiga toxin-producing E. coli refers to strains of E. coli that produce Shiga-like
toxins. Following the first recognition of E. coli O157:H7 in 1982 as a causative agent
of outbreaks of bloody diarrhea, it was soon recognized that other E. coli serotypes
potentially share a similar pathology. This group of E. coli is commonly referred to as
enterohemorrhagic E. coli and represents a defined subset of Shiga toxin-producing E.
coli. E. coli 0157"H7, considered the enterohemorrhagic E. coli prototype, is the most
common and most studied organism in this group. E. coli O157"H7, like all E. coli, is
a gram-negative bacillus; the O refers to the somatic antigen and the H refers to the
flagellar antigen (4).
Unlike the majority of E. coli, E. coli O157"H7 typically do not ferment sorbitol
rapidly (overnight). Therefore clinical stool specimens can easily be screened for E.
coli O157:H7 with the use of Sorbitol MacConkey agar (SMAC). Because of its
inability to ferment sorbitol, E. coli O157"H7 grows after a short incubation as
colorless colonies that are discernible from most other intestinal E. coli strains that
ferment sorbitol and grow as pink colonies. In addition to SMAC, cefixime-tellurite-
SMAC (CT-SMAC) provides a more selective media to isolate E. coli O157 by
inhibiting the growth of normal enteric flora. Non-sorbitol fermenting colonies can
then be identified using an O157 agglutination test; the H7 antigen is also detected with
the use of a latex reagent (5).
Other methods for screening and isolating E. coli 0157 are also available,
though not as widely used. Enzyme-linked immunosorbent assays (ELISA) allow for
rapid screening of stool specimens for O157 antigen. Their overall sensitivity is
comparable to SMAC for detecting E. coli O157. Polymerase chain reaction (PCR)
can be used to determine the presence of genes encoding the O157 antigen. Positive
ELISA or PCR results can only be confirmed by culture. To date, the most sensitive
method for isolating E. coli O157 is the use of an immunomagnetic separation (IMS)
procedure whereby fecal samples are pre-enriched and then incubated with magnetic
beads coated with anti-O 157 antibody. Beads with bacteria attached are then separated
by magnetic force and plated onto SMAC or CT-SMAC. The IMS enrichment
procedure has been shown to significantly increase the isolation rate of E. coli O157 as
compared to direct plating (5).
The microbiological diagnosis of non-O157 STEC is more complex because
non-O157 STEC lack simple growth markers that would distinguish them from
nonpathogenic E. coli strains. Non-O157 STEC ferment sorbitol and would therefore
be overlooked on SMAC or CT-SMAC. However, all non-O157 STEC do share a
common feature the production of Shiga toxin. Therefore, methods for screening and
isolating these strains are based on the detection of Shiga toxin or Shiga toxin genes
Recently, commercial ELISA kits for the detection of Shiga toxin in stool
samples have become available. For maximum sensitivity, these methods require
inoculation of stool in broth to enhance growth of toxin-producers. One particular kit,
Premier EHEC assay, was evaluated in clinical studies and found to have satisfactory
sensitivity and specificity (7,8,9). In particular, Kehl et al. found that the Premier
EHEC assay had 100% sensitivity and 99.7% specificity for E. coli O157 compared to
60% sensitivity and 100% specificity using SMAC (7). In addition to improved
sensitivity for detecting E. coli 0157, the Premier EHEC also detected an additional
20% more STEC. Traditional culture methods, including SMAC and CT-SMAC, do
not reveal the presence of non-O 157 STEC. Thus, testing for the Shiga toxin, with the
use of Premier EHEC method, allows for a practical screening procedure for the
presence of STEC, including non-O157 STEC.
STEC infections may also be diagnosed through serologic testing. Serology has
been useful particularly in patients with HUS who are often culture-negative when HUS
is diagnosed. Serologic techniques have also been valuable in the diagnosis of
infections by non-O157 STEC serogroups (10,11,12). However, the use of serologic
diagnosis is limited, as testing is only available through certain reference laboratories.
Pathogenesis
The production of Shiga toxin is responsible for many of the clinical
manifestations as well as life-threatening sequelae of STEC infection. Acquisition of
STEC first begins with oral ingestion of the organisms (typically requiring very low
numbers) that must survive the harsh environment of the stomach and then compete
with other intestinal microorganisms to establish colonization in the gut. STEC
organisms remain in the gut, producing Shiga toxins. The Shiga toxins are then
absorbed by intestinal cells and transported to the bloodstream. This complex process
permits both local and systemic clinical manifestations of STEC infection (6).
Clinical Manifestations
Much has been learned about the spectrum of human disease associated with
O157 STEC. E. coli O157"H7 causes asymptomatic infection, diarrhea, hemorrhagic
colitis (bloody diarrhea), and hemolytic uremic syndrome (HUS) or thrombotic
thrombocytopenic purpura (TTP) (4,6,13).
Hemorrhagic colitis is the most common presentation of E. coli O157"H7
infection. The illness typically begins with severe abdominal cramps and watery
diarrhea. Bloody stools with the amount of blood ranging from streaks to all blood-
usually follow on the second or third day of illness. Vomiting occurs in about half of
patients. Fever occurs in less than one-third of patients and is usually not high. Illness
is often serious enough to result in hospitalization. Patients with non-bloody diarrhea
tend to have less severe illness shorter duration of diarrhea, less number of stools per
day, less vomiting, less abdominal cramps, and less fever. In most patients, illness
typically resolves 6 to 8 days after onset with no sequelae (4).
HUS is a rare but potentially life-threatening complication associated with E.
coli O157"H7 infection. It occurs in 5 10% of reported cases of E. coli O157:H7,
occurring mostly in patients who are aged less than 5 years (4). HUS is characterized
by microanigiopathic hemolytic anemia, thrombocytopenia and acute renal dysfunction
(14). TTP, a similar condition with accompanying neurologic symptoms and signs,
occurs primarily in adults (15).
HUS is the leading cause of acute renal failure in infants and young children.
Approximately 5 % of HUS patients die, and approximately 10% of those who survive
are left with severe sequelae such as end-stage renal disease or chronic brain damage.
An additional 30-50% of survivors experience mild chronic renal damage (15).
The role of non-O 157 STEC in causing human disease is less clearly
understood. Outbreaks of HUS and clusters of illness associated with non-O157 STEC
have been documented. Outbreaks of HUS attributable to E. coli O111"NM occurred
in Italy in 1992 and in Australia in 1995 (16,17). In the US, outbreaks of acute
gastroenteritis caused by E. coli 0104:H21 occurred in Montana in 1994, E. coli
Olll:H8 in Texas in 1999 (18,19). None of the cases in the Montana E. coli
O104:H21 outbreak developed HUS; however; bloody diarrhea was a prominent
feature, occurring in about 90 % of cases (18). HUS was present in 3 % of cases in the
Texas E. coli O 111 "H8 outbreak; and bloody diarrhea occurred in less than 40% of
cases (19).
Studies in Europe of sporadic cases of HUS have also demonstrated non-O157
STEC as causative agents in a number of infections. A prospective study performed in
Germany and Austria in 1997 involving children with HUS found that non-O157
serotypes (including O26"Hll, O26"NM, O55:H6, O103"H2, O103:NM, O111:NM,
O147:NM, and O165"NM) were isolated from stools of 38% of patients who had
culture-confirmed STEC infections (20). Nationwide surveillance of HUS in Italy
found that during 1996 1997, E coli. 0103 and E. coli 026 were diagnosed in 11%
and in 33 % of HUS cases, respectively (21).
Although non-O157 STEC have been shown to be associated with sporadic and
outbreak cases of HUS; they do not appear to be as common a cause of bloody diarrhea
and HUS as O157 STEC. The HUS study conducted in Germany and Austria found
that non-O157 STEC accounted for 38% of HUS patients with culture-confirmed STEC
infections; by comparison, O157 STEC accounted for 62% of HUS patients (20). A
study conducted in Canada found that persons with non-O157 STEC infection were less
likely to have bloody diarrhea than persons with O157 STEC infection (22).
Prevalence
E. coli O157"H7 is estimated to cause 73,000 infections, 22,000
hospitalizations, and 600 deaths in the US each year; by comparison, non-O157 STEC
are estimated to cause 37,000 infections, 11,000 hospitalizations, and 300 deaths (2).
The estimates for non-O157 STEC are likely to be underestimates since non-O157
STEC infections are not routinely reported nationally and many clinical laboratories
cannot identify them.
A limited number of studies in the US have been conducted to determine the
prevalence of non-O157 STEC. A 1993 study of stool samples from children in Seattle
found a rate of isolation for non-O157 STEC (1.1%) lower than that of O157 STEC
(2.9%) (23). A more recent study of diarrheal stool samples from Nebraska found non-
O157 STEC (which included serotypes O111:NM, O26:Hll, O145:NM, O103:H2,
and Orough:H2) to be as prevalent as O157 STEC (24). Studies in other countries,
such as Argentina, Austria, and Belgium, suggest that non-O157 STEC infections are
more common than O157 STEC infections (25,26,27).
Transmission and Risk Factors
Three principal modes of STEC transmission have been established based on
studies of outbreaks. They include foodborne transmission, waterborne transmission,
and person-to-person transmission. In addition, there is increasing evidence that
exposure to farms or animal pens with infected animals can result in transmission.
Foodborne Transmission. Since the first ground beef-related outbreak in 1982,
cattle have been have been known to be a major reservoir for E. coli O157:H7.
Contamination of meat with bovine feces occurs during slaughter or meat processing
and is a major route by which E. coli O157"H7 enters the food chain (28). A number of
outbreak investigations in the US have implicated undercooked ground beef or
hamburgers as a cause of infection (1,29,30). Consumption of other foods of bovine
origin, such as unpasteurized cow milk, has also been implicated (28).
Even in foodborne outbreaks in which beef is not implicated, contamination with
cattle feces is often suspected. These include outbreaks associated with consumption of
lettuce, unpasteurized apple juice or cider, potatoes, alfalfa sprouts, and cantaloupe
(28,31,32,33,34). In these outbreaks, contamination with cattle manure during
harvesting or processing was suspected. Already processed foods (such as pasteurized
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milk and yogurt) that later became cross-contaminated and foods of non-bovine origin
(such as raw goat milk and deer jerky) have also been implicated as vehicles (5,28).
To date, two documented non-O157 STEC outbreaks have been associated with
specific foods. Pasteurized milk was implicated in the 1994 E. coli 0104"H21 outbreak
in Montana v and dry fermented sausage was suspected in the 1995 E. coli Olll’NM
outbreak in Australia (17,18).
Waterborne Transmission. Several outbreaks of E. coli 0157"H7 have been
associated with consuming contaminated drinking water or swimming in lakes or
wading pools. Large waterborne outbreaks associated with contaminated municipal and
well drinking water have been reported in the US (35,36). In addition, outbreaks
involving swimmers who swallowed contaminated water have also been described (37).
In 1999, an E. coli 0121 outbreak occurred in Connecticut and was associated with
swimming in a lake (38).
Person-to-Person Transmission. Because of the low infectious dose of E. coli
O157:H7, person-to-person fecal-oral transmission can easily occur among close
contacts and in settings where personal hygiene may be insufficient. Person-to-person
transmission plays an important role in outbreaks in daycare settings (39,40).
Secondary cases in household contacts attributable to person-to-person transmission
have also been noted (4,5).
Contact with Farm Animals and Farm Visits. Several recent outbreaks in
Pennsylvania and Washington were found to be associated with transmission of E. coli
O157 from farm animals to humans (41). Additionally, recent multi-state case-control
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studies have identified visiting farms with cows as an important risk factor for E. coli
O157 infection (42). The exact mechanism for infection is unclear. However, factors
such as contact with feces on animals during petting, contact with dirt or equipment
around the animal pens, coupled with the lack of hand-washing facilities and increased
hand-to-mouth activities (e.g. eating and drinking) would likely increase the potential
for transmission to occur.
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METHODS
Laboratory Procedures
Beginning in January 1, 2000, all E. coli O157 isolates and Shiga toxin-positive
broths from inoculation of stool specimens are required to be submitted to the CTDPH
State Laboratory for confirmation and further testing. Shiga toxin-positive broths
submitted to the State Laboratory were plated on Sorbitol MacConkey agar (SMAC)
and Cefixime and Tellurite Sorbitol MacConkey Agar (CT-SMAC). Both SMAC and
CT-SMAC were incubated for 18-24 hours.
Sorbitol-negative colonies were tested with an O157 agglutination test. When
positive, further testing was conducted to determine the H-antigen. Finally, all E. coli
O157 isolates were subtyped further by pulse-field gel electrophoresis (PFGE). PFGE
refers to the process of "fingerprinting" DNA fragments from the bacteria. This
molecular analysis of the bacteria allows for the detection of potential outbreaks since
identical PFGE patterns or fingerprints of bacteria from different patients would be
indicative of a potential common source of infection.
When negative for E. coli 0157, a Shiga toxin test (Premier EHEC) was
performed on different colonies and on a sweep of the heavy growth. When positive
for Shiga toxin, E. coli was identified and sent to the Centers for Disease Control and
Prevention (CDC) for serotyping and determination of Shiga toxin type.
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Ascertainment of Case-Patients and Control-Patients
A case-patient was defined as any Connecticut resident with a culture-confirmed
non-O157 STEC infection between February 1, 2000 and January 31, 2001. Two
control groups were identified. The first control group involves all patients with O157
STEC infection. Because of concerns regarding potential biases related to testing
method used (culture versus Shiga toxin testing), a second control group was identified.
The second control group represents a subset of the first control group and includes
O157 detected from Shiga toxin testing only (the same method used to detect all non-
O157 STEC.)
In control group 1, a control-patient was defined as any Connecticut resident
with a culture-confirmed O157 STEC infection, irrespective of how the O157 was
detected (i.e. through culture-based method or Shiga toxin-testing). In control group 2,
a control-patient was defined as any Connecticut resident with a culture-confirmed
O157 STEC infection that was initially found through Shiga toxin testing. Both control
groups were used for analyses of differences in demographics and spectrum of illness.
Enrollment and Interview Procedures
All Connecticut residents with culture-confirmed STEC infections between
February 1, 2000 and January 31, 2001 were enrolled in the study. Patients were
interviewed by telephone using a standardized questionnaire (Appendix). Household
contacts such as a spouse or parent were interviewed on behalf of patients who died or
pediatric patients less than 13 years of age. Patients between the ages of 13 and 18
14
years were interviewed directly once permission from a parent or guardian was granted.
At least five attempts to reach the patient were made, with at least one attempt during
the evening and weekend.
The questionnaire for this study was adapted from instruments used in prior
studies, particularly the E. coli O157"H7 case-control study questionnaire used by the
Active Foodborne Disease Surveillance Project (FoodNet). Additionally, questions
regarding certain exposures were included because those exposures had been implicated
as vehicles for transmission in previously documented outbreaks of STEC.
Clinical information collected on the questionnaire included" symptoms and
complications during illness, history of taking antibiotics and antacids in the month
prior to onset of illness, and history of gastrectomy. Exposure information was
collected for the 7 days prior to onset of illness and included" history of eating out at
restaurants and consumption of specific foods and drinks (e.g. unpasteurized dairy
products, fish, poultry, meats, hamburger/ground beef, flesh salads and vegetables,
flesh fruits, and unpasteurized juices). Information regarding drinking and recreational
water use was also collected. Other potential exposures included travel (out-of-country,
out-of-state); history of visiting farms or petting zoos; contact with farm animals,
reptiles, and household pets; contact with animal manure; contact with diapered
children; and presence of household contacts who were ill with gastrointestinal
symptoms.
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Data Analysis
Results from laboratory-based surveillance were analyzed. The relative
frequency of non-O157 STEC infection compared to E. coli O157 was determined
based on the number of STEC isolated from Shiga toxin-positive broth specimens
submitted to the State Laboratory. Duplicate isolates or broths on the same patient
were omitted from data analysis. Incidence of STEC disease was determined using the
1999 U.S. Census Bureau’s Population Estimates for Connecticut.
A database was created using Epilnfo version 6.04b (CDC, Atlanta, GA) to
enter and analyze data obtained from patient interviews. Differences between case-
patients and control-patients were assessed in terms of their demographic
characteristics, spectrum of clinical illness, food history, and environmental exposures.
For analyses of exposures or risk factors, only case-patients and control group 1 were
assessed. A total of 76 specific food items were analyzed. Approximately 20 other
potential exposures (e.g. eating out, storage of ground beef in refrigerator, handling of
raw meats, travel, contact with farm animals, contact with diapered children) were also
assessed.
Odds ratios, 95 % confidence intervals and P-values were calculated using
Epilnfo 6.04b and StatXact (Cytel Corporation, Cambridge, MA). Wilcoxon two-
sample tests were conducted for comparison of continuous variables. A P-value of
< .05 determined by Chi-square or Fisher exact two-tailed tests was used to establish
statistically significant differences.
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RESULTS
Laboratory Surveillance
Between February 1, 2000 and January 31, 2001, a total of 90 STEC infections
were identified in Connecticut. Sixty-one of these infections were identified directly
through E. coli O157 culture isolates (i.e. isolations from SMAC or CT-SMAC at
clinical laboratories) that were submitted to the State Laboratory.
In addition, forty-one Shiga toxin-positive broths were submitted from five
clinical laboratories in the state. Thirty-two (78 %) broths were confirmed as Shiga
toxin-positive by the State Laboratory. Among those 32 broths, E. coli was isolated
from 29 for an isolation rate of 91%. Seventeen (59%) of the 29 E. coli were
identified as E. coli O157 while 12 (41%) were non-O157 serotypes.
Among the 12 non-O157 STEC isolates, 9 different serotypes were identified"
O8:H14, O26"NM, O91"NM, O103"H2 (3 isolates), O103"H25, O111:H8, O111"NM,
O163"H19, and O undetermined"NM (2 isolates). Eight isolates yielded Shiga toxin
type 1 only, 3 Shiga toxin type 2 only, and 1 Shiga toxin types 1 and 2 (Table 1).
Overall, 78 E. coli O157 isolates were identified" 73 (94%) were E. coli
O157"H7 and 5 (6%) were E. coli O157"NM (non-motile). Seventy-seven isolates
were subtyped further by PFGE. Forty-one different PFGE patterns were determined
among the 77 E. coli O157 isolates. The most common patterns were EX1.079 (7
isolates), EX1.041 (6 isolates), and EX1.037, EX1.117, EXl.125 (5 isolates each).
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Several PFGE-defined clusters were identified during the study period; however, no
known common exposures could be associated with the cases.
Crude Incidence, Projected Incidence, and Seasonal Variation
Overall, ninety culture-confirmed STEC infections among Connecticut residents
were reported between February 1, 2000 and January 31, 2001. Twelve infections
were caused by non-O157 STEC (case-patients) and 78 were caused by O157 (control-
patients). The overall crude incidence of STEC infection in Connecticut was 2.7 cases
per 100,000 population. Crude incidence of non-O157 STEC infection was 0.4 cases
per 100,000 population compared with 2.4 cases per 100,000 population for O157
STEC infection.
Extrapolating from results of Shiga toxin testing, we would expect to have an
additional 43 non-O157 STEC detected if all clinical laboratories conducted Shiga toxin
testing. Therefore, the estimated annual number of STEC infection in Connecticut is
133 cases for a projected overall annual incidence of 4.1 cases per 100,000 population.
The projected annual incidence of non-O157 STEC is 1.7 cases per 100,000 population
compared with 2.4 cases per 100,000 for O157 STEC infection.
Monthly and seasonal distribution of non-O157 STEC and O157 STEC were
similar (Figure 1 and Figure 2). Overall, 38 (42 %) STEC infections occurred between
the summer months of June and August. Thirty-two (41%) O157 and 6 (50%) non-
O157 STEC occurred during this period.
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Patient Characteristics
Sex, Age, County, and Race. The demographic characteristics of patients with
STEC infections are summarized in Table 2 and Table 3. There were no significant
differences between case-patients and control-patients (both groups 1 and 2) in terms of
age, county of residence, and race or ethnicity. When compared to group 2 control-
patients, case-patients were more likely to be female (P= .04).
Spectrum of Illness
The clinical manifestations of STEC infection in both case-patients and control-
patients are summarized in Table 4 and Table 5. Among case-patients, 83 %
experienced diarrhea that ranged from 3 41 days (median 8 days). Two patients
reported no diarrhea; one was tested because of concern over one episode of bloody
stool, the other was tested because of concern over a persistent lack of appetite. Other
symptoms reported by case-patients include cramps (75 %), nausea (50%), headache
(50 %), fever (50 %), bloody stool (42 %), and vomiting (33 %). Only one (8 %) case-
patient was hospitalized; this patient was hospitalized for 8 days. No case-patient
developed HUS or had a fatal outcome.
Among control group 1 patients, 100% experienced diarrhea that ranged from 1
15 days (median 5 days). Other symptoms reported include cramps (95 %), bloody
stool (88 %), nausea (57 %), fever (50 %), vomiting (45 %), and headache (25 %). Forty
(53 %) patients were hospitalized; the mean number of days hospitalized was 8. Ten
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(13%) patients had HUS/TTP. Death occurred in two (3%) patients, aged 12 and 82
years.
Among control group 2 patients, 100% experienced diarrhea that ranged from 2
to 12 days (median 4). Other symptoms reported include cramps (95 %), bloody stool
(77%), vomiting (53 %), fever (41%), nausea (41%), and headache (12%). Five (29%)
patients were hospitalized; the mean number of days hospitalized was 4. One (6 %)
patient developed HUS/TTP. No death occurred among patients in control group 2.
Compared with patients in control group 1, case-patients were significantly less
likely to have experienced any diarrhea (OR=0, P= .02), less likely to have bloody
diarrhea (OR-0.10, p-0.001), and less likely to have been hospitalized (OR=0.08,
P=.01) (Table 4). Compared with patients in control group 2, case-patients were
significantly more likely to have experienced headaches (OR=7.5, P=.04). They were
also less likely to have experienced diarrhea, bloody diarrhea, and hospitalization; but
these differences could have occurred by chance (P > .05) (Table 5).
Severe complications of HUS/TTP occurred only among patients with O157
infections. The median age of patients who developed HUS/TTP was 3.5 years. Seven
(70%) were female. HUS patients were hospitalized for a median of 14 days (range 9
to 52 days).
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Exposures and Risk Factors
One case-patient was excluded from analysis of exposure because a date of onset
of illness could not be determined. Two control-patients were excluded from analysis
of exposures because they were unreachable for interviews.
Seventy-six specific food items were assessed. No single food exposure showed
a statistically significant difference (P < .05 and a 95 % confidence interval that does
not include 1). Food items showing the strongest associations and other exposures of
interest are presented in Table 6. Items with the strongest positive associations were all
fruits or vegetables. No differences in water, and environmental exposures were
identified between case-patients and control-patients.
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DISCUSSION
The role of non-O157 STEC in human disease and its relative contribution to the
burden of enteric illness in the US is largely unknown. Few studies have been done to
characterize the prevalence and epidemiology of non-O157 STEC infection. This is
largely due to the fact that, historically, testing for E. coli O157 does not detect non-
O157 STEC. However, recent changes in laboratory practices have provided this new
opportunity to assess the role of non-O157 STEC infection in Connecticut.
Results from this study suggest that, in Connecticut, non-O157 STEC are almost
as prevalent as O157 STEC. Non-O 157 STEC were identified in 41% of Shiga toxin-
positive broths in which E. coli was isolated; O157 STEC was identified in the
remaining 59 %. However, because the number of laboratories testing for Shiga toxin
is significantly less than the number of laboratories using culture-based methods, the
contribution of non-O157 to overall STEC illness reported is only 13%; 12 non-O157
STEC were identified out of a total of 90 STEC during the 12-month study period.
Accordingly, the crude incidence of non-O157 STEC (0.4 case per 100,000) is much
lower than that of O157 STEC (2.4 cases per 100,000 population).
Based on data from surveillance of Shiga toxin positive broths, if all clinical
laboratories in Connecticut conducted Shiga toxin testing, an additional 43 non-O157
STEC would have been detected during the study period. Thus the estimated annual
number of STEC infections in Connecticut would be 133 cases, for an estimated annual
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incidence of 4.1. Non-O157 STEC would account for 41% of all STEC as opposed to
only 13 % of all STEC.
Currently, in Connecticut, 7 of 34 clinical laboratories conduct Shiga toxin
testing in order to detect of E. coli. These laboratories are located in the following
counties" 3 in New Haven, 2 in Hartford, 1 in Fairfield, and 1 in Tolland. Over 60%
of Shiga toxin positive broths were submitted from one laboratory, a high volume
outpatient laboratory (located in New Haven County) that serves physicians throughout
the state. It is likely that additional laboratories in Connecticut will adopt Shiga toxin
testing. A recent follow-up survey by FoodNet found that an additional 16 laboratories
in Connecticut are considering adopting Shiga toxin testing. With the prospect of
additional clinical laboratories using Shiga toxin testing in the near feature,
identification of non-O157 STEC is likely to increase.
Important differences in the clinical spectrum of illness between persons with
non-O157 STEC and persons with O157 STEC infections were noted. When compared
to all 0157 cases (irrespective of the testing method used), persons with non-O157
infections were significantly less likely to experience diarrhea, bloody stool, and
hospitalization. This may be explained by the fact non-O157 STEC infections were
only detected through Shiga toxin testing and that over 60% of Shiga toxin positive
specimens were submitted by one outpatient laboratory. Persons with less severe
symptoms (such as non-bloody diarrhea) and few complications would more likely be
tested and treated as outpatients.
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When compared only to O157 cases identified through Shiga toxin testing, the
differences persisted but could have occurred by chance (P > .05). This may be
because of the small number of O157 cases (17 STEC O157). Of note is the fact that
no patient with non-O157 STEC developed HUS/TTP, while 10 O157 patients
developed HUS/TTP and two died. While this difference could have been a chance
finding, this study suggests that persons with non-O157 STEC had less severe illness
than persons with O157 infection. It will be important to see if these findings persist in
future years.
Given multiple comparisons considerations, there was no particular exposure
that reached a statistical significance level of P < .05 and a 95 % confidence interval
that does not include 1. This suggests that risk factors for non-O157 STEC may not be
all that different from risk factors for O157 STEC. Since the first E. coli O157:H7
outbreak, it has been established that cattle are natural reservoir for the organism and
undercooked ground beef is a major vehicle for transmission. There is also evidence
that STEC of multiple serotypes are present in cattle feces and that non-O157 STEC
have also been isolated from ground beef (43). This evidence indicates that
contaminated ground beef is potentially capable of causing non-O157 as well as 0157
STEC infections. Additionally, it has been suggested that human exposure to non-O157
STEC is more common and frequent than is exposure to O157 STEC (44). Therefore
the potential for human disease caused by non-O157 STEC is high.
The fact that food items with the strongest associations were all fruits or
vegetables is of interest. It is conceivable that O157 is more adapted to cattle than
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other STEC, and that STEC, like other E. coli occupy a broader ecological niche than
animal intestines. Continued study of this difference will be valuable.
The percentage of O157 cases involving females was steady between 1992 and
1996" 58% in 1992, 51% in 1993, 53% in 1994, 57% in 1995, 58% in 1996. Between
1997 and 2000, a gradual increase in the percentage of female was observed: 43 % in
1997, 50% in 1998, 60% in 1999, and 67 % in 2000. A possible hypothesis for this is
that educational messages regarding avoidance high-risk foods such as raw or
undercooked meat (particularly beef and ground beef) may have played a role in the
decrease observed among males (who tend eat undercooked meats).
This study had several limitations. Control subjects were patients with O157
infections rather than the "ideal" control group of well persons in the community.
Therefore this study only allowed for an attempt at identifying exposures that would
increase the frequency of non-O157 STEC relative to O157 STEC infection. In the
analysis of exposures, issues of multiple comparisons should be considered, as a blind
search was done of 76 different possible exposures. Additionally, the number of cases
was small, particularly for non-O157 STEC. Thus, the chance of finding meaningful
differences was small, even if there are true differences.
This study has shown that, in Connecticut, surveillance for Shiga toxin-related
diseases is a valuable adjunct to surveillance solely for E. coli O157:H7. Changes in
laboratory practices have necessitated the adoption of STEC surveillance that is not
specific to just O 157 STEC. Mandatory reporting and submission of clinically positive
Shiga toxin broth specimens is necessary for several reasons. Submission of positive
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broths allows the State Laboratory to confirm the presence of Shiga toxin. This is
important because non-culture rapid assays to detect Shiga toxin can be subject to false
positives. Submission of positive broths also enables the State Laboratory to conduct
further testing to culture and identify the causative organism. Identification of the
STEC serotype and molecular subtyping (PFGE) of isolates aide in the detection and
investigation of outbreaks. A recent outbreak of Calicivirus infection in Virginia was
initially mistakenly attributed to STEC O157 (45). This outbreak highlights the
importance of state laboratory confirmation and follow-up cultures of Shiga toxin-
positive broths.
Ongoing surveillance for both O157 and non-O157 STEC is needed to better
define the incidence of STEC infections in Connecticut. Continued monitoring of
changes in testing methods by laboratories would be useful in interpreting surveillance
data; this can be done through periodic surveys of laboratories concerning testing
procedures. Further studies are needed to better characterize the clinical features and
epidemiology of STEC infections. As more non-O157 cases are identified, more in
depth analyses such as spectrum of illness by different non-O157 serotypes can be
attempted. This level of analysis was beyond the scope of this study since there were
too few non-O157 cases. Finally, additional epidemiologic studies using well controls
would allow for better assessment of risk factors associated with non-O157 infection.
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Table 1. Non-O157 STEC Serotypes, Connecticut, February 1, 2000-
January 31, 2001.
O-antigen
0103
0103
0103
0103
0111
0111
0163
026
08
091
undetermined
undetermined
H-antigen
H2
H2
H2
H25
H8
NM
H19
NM
H14
NM
NM
NM
Shiga toxin (Stx) type
Stxl
Stxl
Stxl
Stxl
Stxl
Stxl
Stx2
Stxl
Stx2
Stx1, Stx2
Stxl
Stx2
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Table 2. Comparison of Case-Patients (non-O157) and Control Group 1 Patients
(all O157) by Demographic Factors, February 1, 2000 January 31, 2001.
Demographic
Characteristics
Age (Years)
< 10
10- 19
20 29
30 39
40 49
50 59
60 69
70- 79
> 79
Age range, years
Mean age (median), years
Case-Patients
(non-O157)
n= 12
No. (%)
4 (33 %)
4 (33 %)
2(17%)
0(0%)
1 (8%)
1 (8%)
0(0%)
0 (0%)
o (o)
1-54
18(13)
Control Group 1
Patients
(all O157)
n = 78
No. (%)
25 (32%)
18 (23 %)
4 (5%)
3 (4%)
3 (4%)
9(12%)
6(8%)
7 (9%)
3 (4%)
1-90
30 (17)
Sex
Male
Female
County
Fairfield
Hartford
Litchfield
Middlesex
New Haven
New London
Tolland
Windham
Race/Ethnicity
White
Black
Hispanic
Asian
Unknown
No. (%)
3 (25 %)
9 (75%)
No. (%)
6(50%)
2(17%)
1 (8%)
1 (8%)
0(0%)
0(0%)
2(17%)
O(O%)
No. (%)
10 (83 %)
1 (8%)
0(0%)
1 (8%)
0(0%)
No. (%)
26 (33 %)
52 (67%)
No. (%)
13(17%)
17 (22%)
4 (5%)
6(8%)
20 (26 %)
10(13%)
5 (6%)
3 (4%)
No. (%)
70 (90%)
1 (1%)
4 (5%)
1 (1%)
2 (3%)
P-value
0.74*
0.26**
0.05*
0.22*
* Fisher exact test, r x c contingency table (StatXact)
** Wilcoxon two-sample test
Chi-squared test for 2 x 2 contingency table
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Table 3. Comparison of Case-Patients (non-O157) and Control Group 2 Patients
(STEC O157) by Demographic Factors, February 1, 2000 January 31, 2001.
Demographic
Characteristics
Age (Years)
< 10
10- 19
20 29
30 39
40 49
50 59
60 69
70- 79
> 79
Age range, years
Mean age (median), years
Case-Patients
(non-O157)
n = 12
No. (%)
4 (33 %)
4 (33 %)
2(17%)
0(0%)
1 (8%)
1 (8%)
0(0%)
0 (0%)
o (0%)
Control Group 2
Patients
(STEC O157)
n= 17
No. (%)
6 (35 %)
7 (41%)
1 (6%)
0(0%)
1 (6%)
0 (0%)
1 (6%)
1 (6%)
0 (O%)
Sex
Male
Female
County
Fairfield
Hartford
Litchfield
Middlesex
New Haven
New London
Tolland
Windham
Race/Ethnicity
White
Black
Hispanic
Asian
Unknown
1-54
18(13)
No. (%)
3 (25.0%)
9(75.0%)
No. (%)
6 (50%)
2(17%)
1 (8%)
1 (8%)
o (0%0
0(0%)
2(17%)
o(o%)
1-72
20 (13)
No. (%)
11 (65%)
6 (35 %)
No. (%)
3(18%)
2(12%)
1 (6%)
1 (6%)
6 (35 %)
1 (6%)
3(18%)
O(O%)
No. (%)
10 (83 %)
1 (8%)
o (0%)
(8%)
0(0%)
No. (%)
17 (100%)
0(0%)
0(0%)
o (0%)
0(0%)
P-value
0.89*
0.98**
0.04^
0.18"
0.16"
* Fisher exact test, r x c contingency table (StatXact)
** Wilcoxon two-sample test
^ Chi-squared test for 2 x 2 contingency table
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Table 4. Comparison of Case-Patients (non-O157) and Control Group 1 Patients
(all O157) by Symptoms and Complications, February 1, 2000 January 31,2001.
Symptoms and
Complications
Diarrhea
Blood in stool
Nausea
Vomiting
Cramps
Headache
Fever
Hospitalized
HUS/TTP
Death
Case-Patients
(non-O157)
n = 12
n* % with
12 83%
12 42%
12 50%
12 33%
12 75%
12 50%
12 50%
12 8%
12 0%
12 0%
Control Group
1 Patients
(all O157)
n = 78
n* % with
76 100%
73 88%
69 57%
74 45%
74 95%
71 25%
70 50%
76 53%
76 13%
76 3%
OR (95% CI) P-
value
0 (0-0.61) 0.02
0.10 (0.02-0.46) 0.001
0.77 (0.19-3.06) 0.68
0.62 (0.14-2.56) 0.47
0.17 (0.03-1.17) 0.05
2.94 (0.72-12.16) 0.10
1.00 (0.25-3.96) 1.00
0.08 (0-0.67) 0.01
0 (0-3.35) 0.35
0 (0-28.59) 1.00
* Number of patients for whom information was available.
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Table 5. Comparison of Case-Patients (non-O157) and Control Group 2 Patients
(STEC O157) by Symptoms and Complications, February 1, 2000
January 31,2001.
Symptoms and
Complications
Diarrhea
Blood in stool
Nausea
Vomiting
Cramps
Headache
Fever
Hospitalized
HUS/TTP
Death
Case-Patients
(non-O157)
n= 12
n* % with
12 83%
12 42%
12 50%
12 33%
12 75%
12 50%
12 50%
12 8%
12 0%
12 0%
Control Group
2 Patients
(STEC O157)
n= 17
n* % with
17 100%
17 77%
17 41%
17 53%
17 95%
17 12%
17 41%
17 29%
17 6%
17 0%
OR (95% Cl) P-
value
0 (0-2.98) 0.16
0.22 (0.03-1.39) 0.12
1.43 (0.25-8.25) 0.64
0.44 (0.07-2.61) 0.30
0.19 (0.01-2.62) 0.28
7.5 (0.91-76.28) 0.04
1.43 (0.25-8.25) 0.64
0.22 (0.01-2.58) 0.35
0 (0-26.34) 1.00
NC
* Number of patients for whom information was available.
NC not computable
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APPENDIX
E. coli O157 and Shiga-toxin Related Disease Questionnaire
Name (Last, First):
City:
Parent’s name (if child):
E. coli "O" antigen
Shiga-toxin positive test:
Age: Sex: M F
County: Phone:
"H" # PFGE Collection date:
yes no PHLIS ID Interviewer: Date:
Section 1. Illness History. I would like to begin by askingyou about some ofthe symptoms you may have experienced.
1. Date of onset: / Time of onset:
Nausea yes no dk/ns
Vomiting yes no dk/ns
Diarrhea yes no dlns
If yes, date of onset of diarrhea: __/ /__
Greatest # stools in a 24 hour period
Duration of diarrhea (days):
Blood in stool yes no dk/ns
If yes, how much blood? (read thefollowing descriptions)
1. small amount or streak ofblood (mixed with stool)
2. gross amount ofblood (mixed with stool)
3. all blood
9. dk/ns
Cramps yes no dlns
Headache yes no dk/ns
Fever yes no dk/ns
If yes, what was the highest temperature recorded?
HUS yes no dlns
TTP yes no dk/ns
AM PM
time of onset: AM PM
2. Did you visit a hospital emergency room or a doctor’s office because of this illness?
If yes, number of times (include both ER and office visits)
yes no dk/ns
3. Were you admitted to the hospital ovemight for this illness? yes
If yes, number of nights Admit date:
no dk/ns
/__ Hospital:
4. Have you had your blood drawn for any reason because of this illness?
If yes, where did you have the blood drawn?
yes no dk/ns
and when
5. Because of this illness, did you miss any time from work (or school, daycare for pediatric cases)? yes
If yes, how many total days did you miss more than 4 hours from work (or school) due to this illness?
no dk/ns
6. Were you treated with antibiotics for this illness?
If yes, which antibiotic(s)?
yes no dlns
7. During the 4 weeks prior to this illness, were you taking antibiotics for any reason?
If yes, which antibiotic(s)?
yes no dk/ns
8. During the 4 weeks prior to this illness, were you taking any antacids (such as, Maalox, Tagamet, Pepcid or Zantac) on a
regular basis? yes no dk/ns
If yes, which antacid(s) were you taking?
9. Prior to this illness, did you have a gastrectomy (surgery to remove part of your stomach or intestine)? yes no dk/ns
10. Do you know of anyone else who has had these symptoms during the week before or after you became ill?
If yes, who:
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Did they see a doctor or visit a clinic for their illness? yes
If yes, doctor/clinic name and location:
Did they submit a stool specimen for testing? yes no
no dk/ns
dk/ns
Section 2. Open-ended Food History. Please try to remember whatyou may have eaten in the 5-day period before
you startedfeeling sick. We’ll start with the day before you got sick and work backwards. (Ira meal was eaten out, specify
where.)
Day 1 __/__/
BrealgCast Lunch Dinner Other
home or out home or out home or out
Day 2 __/ /
Breakfast Lunch Dinner Other
home or out home or out home or out
Day 3 __/__/__
Breakfast Lunch Dinner Other
home or out home or out home or out
Day 4 __/__/
Breakfast Lunch Dinner Other
home or out home or out home or out
Day 5 __/__/__
Breakfast Lunch Dinner Other
home or out home or out home or out
Section 3. Restaurants and Grocery Stores
11. In the 7 days before your diarrhea began, how many times did you eat from a fast food chain restaurant?
1.0 2.1-3 times 3.4-6 times 4. > 7 times 9. dk/ns
What were the names and locations of the fast-food restaurants?
Name Location
Name Location
Name Location
Name Location
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12. How many times did you eat out at any other restaurants?
1.0 2.1-3 times 3.4-6 times
What were the names and locations of those restaurants?
Name
Name
Name
Name
4. > 7 times 9. dk/ns
Location
Location
Location
Location
13. Did you eat any food from a salad bar? yes no dk/ns
14. Where did you purchase groceries that were eaten during the 7 days before your illness (including specialty stores,
produce or fruit stands, dairy marts, etc.)?
Name Location
Name Location
Name Location
Name Location
Section 4. Detailed Food History. Now I’d like to askyou about specificfood items that you may have eaten.
During the 7 days before you got sick, didyou eat thefollowing items?
A. Dairy Products
Milk, unpast yes no dk/ns
Icecream, unpast yes no dk/ns
Yogurt, unpast yes no dk/ns
Cheese, unpast yes no duns
Soft cheeses yes no dlns
brie yes no dk/ns
caso fresco yes no dk/ns
cottage cheese yes no dk/ns
cream cheese yes no dk/ns
feta yes no dlns
mozzarella yes no dk/ns
ricotta yes no dk/ns
other (soft) yes no dk/ns
Other cheeses yes no dk/ns
Comments (variety howprepared, where bought etc.)
unpasteurized? yes no dlffns
unpasteurized? yes no dk/ns
unpasteurized? yes no dk/ns
unpasteurized? yes no dlns
unpasteurized? yes no dk/ns
unpasteurized? yes no dlffns
unpasteurized? yes no dk/ns
unpasteurized? yes no dlns
specify
B. Fish, Poultry, and Meats
Fish yes no dk/ns
Shellfish yes no dk/ns
(such as shrimp, lobster, clams, etc.)
Chicken yes no dk/ns
Turkey yes no dlffns
Pork yes no dk/ns
Veal yes no dk/ns
Lamb yes no dlffns
Venison yes no dk/ns
Sausage yes no dlffns
Hot dog yes no dlffns
Beefjerky yes no dlffns
Dried salami yes no dlffns
Deli meats yes no dk/ns
Roast beef yes no dlffns
Steak yes no dk/ns
specify
specify
C. Hamburger and Ground Beef
Hamburger yes no dk/ns
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If yes, was hamburger(s) eaten at home or out? 1. at home 2. out, where
How was the hamburger cooked? 1. rare (red in middle) 2. medium (pink in middle)
For hamburger(s) eaten in the home, was it made from (also ask where item was purchasedfrom):
Fresh (never frozen) raw ground beef
Previously frozen raw ground beef
Pre-made uncooked patties
Pre-made, pre-cooked patties
Other ground beef such as in a taco, meatloaf, etc.
If yes, specify dish
3. both
3. well done (no pink)
yes no dk/ns
yes no dk/ns
yes no dk/ns
yes no dk/ns
yes no dlns
eaten at home or out, where
INDIRECTEXPOSURE TO HAMBURGERAND GROUND BEEF IN THE HOME SETTING
Ifpatient did not answer "yes" to eating some type ofhome-prepared hamburger or ground beef ask thefollowing.
Was there any ground beef stored in your refrigerator in the 7 days before your illness? yes no
Did you or someone in your household prepare a meal for others that contained ground beef?, yes no
dk/ns
dk/ns
INDIRECTEXPOSURE TO OTHER RAWMEATS (askfor ALL patients)
Did you handle any raw meat at home or anywhere else in the 7 days before your illness?
If yes, what kind of meat(s) was it?
yes no dk/ns
D. Fresh/Uncooked Salads and Vegetables
Tabouleh salad yes no dlns
Cole slaw yes no dk/ns
Prepackaged yes no dlns
salad (specify what items are in the salad)
Lettuce yes no dk/ns
Iceberg yes no dlns
Green leaf yes no dlns
Red leaf yes no dk/ns
Romaine yes no dk/ns
Mesclun yes no dlns
(also called mixed greens)
Other yes no dk/ns
Alfalfa sprouts yes no dk/ns
Other sprouts yes no dk/ns
Spinach yes no dk/ns
Cabbage yes no dk/ns
Tomatoes yes no dk/ns
Carrots yes no dk/ns
Broccoli yes no dk/ns
Celery yes no dlns
Squash yes no dk/ns
Eggplant yes no dk/ns
Mushrooms yes no dlns
Peppers yes no dlns
Onions yes no dldns
Scallions yes no dk/ns
(also called green onions)
Radishes yes no dk/ns
Parsley yes no dk/ns
Cilantro yes no dlns
Basil yes no dk/ns
E. Fresh Fruits
Watermelon yes no dlUns
Cantaloupe yes no duns
Honeydew melon yes no dk/ns
regular/large or cherry tomatoes
regular/large or baby carrots
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Grapefruit yes no dk/ns
Oranges yes no dk/ns
Pears yes no dk/ns
Plums yes no dk/ns
Nectarines yes no dlns
Peaches yes no dk/ns
Apples yes no dlns
Grapes yes no dk/ns
Strawberries yes no dlffns
Raspberries yes no dlffns
Blueberries yes no dk/ns
Other berries yes no dlffns
Kiwi yes no dlffns
Mango yes no dlffns
Pineapple yes no dlffns
Avocado yes no dk/ns
APPENDIX
red or green?
EXPOSURE TO ORGANICALLY GROWNPRODUCE
Were any of the produce (fruits and vegetables) you consumed organically grown?
If yes, what
yes no dk/ns
F. Unpasteurized Juices
Apple juice/cider yes no dlns
Orange juice yes no dk/ns
Smoothie yes no dk/ns
Other juices yes no dk/ns
G. Drinking Water at Home
Private well yes no
Municipal yes no
What company?
dlns
was it made from concentrate?
was it made from concentrate?
specify
specify
any from concentrate?
any from concentrate?
Water chlorinated? yes no dk/ns
Note." Ask thefollowing question(s) ifthe patient indicates thathe drinksfrom the tap but does not know whether the
water isfrom a private well or a municipal system."
Do you receive a bill from a water company? yes no dk/ns
If yes, what is the name of the company?
Bottled water yes no dlns
Pond/lake/river yes no dk/ns
Other yes no dk/ns
H. Drinking Water Outside of the Home
Private well yes no dk/ns
Municipal yes no dk/ns
Bottled water yes no dk/ns
Pond/lake/river yes no dlns
Other yes no dlns
specify
chlorinated?
specify
Section 5. Other Exposures. (During the 7 days before onset of diarrhea.)
15. Did you travel out of the country? yes no
If yes, where?
16. Did you travel to any other state(s)? yes no
If yes, where?
dk/ns
dk/ns
17. Did you do any swimming or wading? yes no
When? from
When? from
When? from
dlns
If yes, what type of swimming area was it? (inquire about location ofswimming area)
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to
to
Wading or kiddie pool yes
Outdoor swimming pool yes
Indoor swimming pool yes
Hot tub, jacuzzi or spa yes
Pond, lake, river or stream yes
Other yes
Did you submerge your head under water?
Did you swallow any water?
APPENDIX
no
no
no
no
no
no
yes no
yes no
dlns
18. Did you attend any large gatherings (parties, festivals, fairs, etc.)?
If yes, where/when/foods
yes no dlns
19. Did you have direct contact with any farm animals?
If yes, what kind of animal(s)?
yes no dk/ns
Where
20. Did you visit a farm or petting zoo at which there were animals? yes no
If yes, where What kind of animals were there?
dkfns
21. Did you have contact with animal manure as might occur during farming, gardening, or caring for animals?
yes no dk/ns
If yes, what kind of activity were you involved in?
22. Did you have contact with reptiles (snakes, lizards, turtles)?
If yes, what kind
yes no dldns
Where
23. Did you have contact with household pets?
If yes, what kind
yes no dk/ns
24. Are there any children in your household in diapers? yes no
25. Did you change any diapers or otherwise handle dirty diapers? yes
dk/ns
no dk/ns
Section 6. High Risk Occupations and Activities
26. What is your occupation?
27. Do you handle or prepare food as part of your duties?
If yes, describe
yes no dk/ns
28. Do you provide health care?
If yes, describe
yes no dk/ns
Provide direct patient care? yes no dlns
29. Do you attend (for child) or work (for adult) in a daycare setting?
If yes, describe
yes no dk/ns
Are you aware of any other illness in the daycare? yes no dkfns
Section 7. Demographics
What is your race?
1. White 3. Asian, Pacific Islander
2. Black 4. American Indian
Are you of Hispanic origin?
1. Yes 3. No
2. Refused 4. dlns
5. Other, specify
6. Refused
9. dk/ns
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